A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LUAD / lung adenocarcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 356
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LUAD  (>> Co-occurring Abbreviation)
Long Form:   lung adenocarcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. CT, CT-lncRNA
2019 A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. AK, IHC
2019 A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association. KIRP, OV
2019 A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies. DCA, GEO, LASSO, OS, RFS
2019 A new method for excavating feature lncRNA in lung adenocarcinoma based on pathway crosstalk analysis. lncRNAs, NSCLC, PAGI, WGCNA
2019 A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis. GEO, GSEA, LNM, t-ROC
2019 A novel LncRNA-based prognostic score reveals TP53-dependent subtype of lung adenocarcinoma with poor survival. LncRNA, LPS, WT
2019 A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma. circRNA
2019 A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma. lncRNA, RFS
10  2019 A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma. AKT, NTRK2
11  2019 A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. AUC, ceRNA, circRNAs, DEcircRNAs, GEO, GO, KEGG, qRT-PCR, ROC
12  2019 Adaptive protein translation by the integrated stress response maintains the proliferative and migratory capacity of lung adenocarcinoma cells. ASNS, ISR, ISRIB
13  2019 An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma. LUSC, NSCLC, TME
14  2019 An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma. 5'UTR, HOX, NAT
15  2019 Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. PD-L1
16  2019 ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway. ATAD2, FDG, GLUT1, HK2, TLG
17  2019 ATMIN is a tumor suppressor gene in lung adenocarcinoma. ---
18  2019 Bioinformatics analysis of microarray data to identify the candidate biomarkers of lung adenocarcinoma. DEGs, GEO, PPI, STRING
19  2019 Can CpG methylation serve as surrogate markers for immune infiltration in cancer? GBM, HNSC, KICH, KIRC, KIRP, LGG, LUSC, MESO
20  2019 Cascaded Wx: A Novel Prognosis-Related Feature Selection Framework in Human Lung Adenocarcinoma Transcriptomes. C-index, CWx
21  2019 CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. ---
22  2019 CENPE promotes lung adenocarcinoma proliferation and is directly regulated by FOXM1. CENP-E, FOXM1
23  2019 Characterization of lung adenocarcinoma with a cribriform component reveals its association with spread through air spaces and poor outcomes. OS, RFS, STAS
24  2019 CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway. ChPF, qPCR
25  2019 CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/beta-catenin signaling pathway. circRNAs
26  2019 Circular RNA circ-TSPAN4 promotes lung adenocarcinoma metastasis by upregulating ZEB1 via sponging miR-665. circRNA, GEO, qRT-PCR
27  2019 Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway. qRT-PCR
28  2019 Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. ctDNA, LASSO, LUSC, MAF, NGS, NSCLC, post-op, pre-op, tDNA
29  2019 Clinical value of microRNA-198-5p downregulation in lung adenocarcinoma and its potential pathways. KEGG, RT-qPCR
30  2019 Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. GSEA, NSCLC
31  2019 Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma. ROS, UGTs
32  2019 Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients. ARMS, ctDNA, EGFR, EGFR-TKI
33  2019 Comprehensive analysis of tumor immune infiltration associated with endogenous competitive RNA networks in lung adenocarcinoma. ---
34  2019 Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data. AUC, GEO, HOXA10, LUSC, NSCLC
35  2019 Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma. CNAs, FFPE
36  2019 Construction of a transcription factor‑long non‑coding RNA‑microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. lncRNAs, LUSC, miRNAs, TFs, TML
37  2019 CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer. CNAs, CPSF
38  2019 Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data. LUSC, miRs
39  2019 Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. CGP, NGS, TMB
40  2019 Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. NGS, NSCLC
41  2019 Development and Validation of a Novel Signature to Predict Overall Survival in "Driver Gene-negative" Lung Adenocarcinoma (LUAD): Results of a Multicenter Study. ---
42  2019 Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas. COAD, MFR
43  2019 Digital Inference of Immune Microenvironment Reveals "Low Risk" Subtype of Early Lung Adenocarcinoma. IME, OS
44  2019 Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. PP2A, TKIs
45  2019 Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. ---
46  2019 Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response. ---
47  2019 DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell. ---
48  2019 EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. HIF, NSCLC
49  2019 Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. ---
50  2019 Epigenetic-Mediated Downregulation of Zinc Finger Protein 671 (ZNF671) Predicts Poor Prognosis in Multiple Solid Tumors. BRCA, CESC, HNSC, KIRP, KM plotter, PAAD, UCEC, ZNF671
51  2019 Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. EMT
52  2019 ERRalpha is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes. ERRalpha, KM, LSCC
53  2019 ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2. ---
54  2019 Exploration of the hub genes and miRNAs in lung adenocarcinoma. TFs
55  2019 Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. CTSE, FDR, KEGG, SLC5A7
56  2019 Expression levels and co‑targets of miRNA‑126‑3p and miRNA‑126‑5p in lung adenocarcinoma tissues: Alphan exploration with RT‑qPCR, microarray and bioinformatic analyses. LNM, miRNAs, TNM
57  2019 Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma. CR, lncRNAs, LUSC, NSCLC, PD, PR, RFS, SD, SUMO-1, SUMO1P3
58  2019 FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma. ---
59  2019 FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14. EMT, lncRNAs
60  2019 Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). RIN
61  2019 Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis. DEGs, LUSC
62  2019 FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma. EMT
63  2019 Function of low ADARB1 expression in lung adenocarcinoma. 5-azaD, A-to-I, ADARB1, FP, GEPIA, OS, PPS
64  2019 FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. GSEA, OS
65  2019 Gene expression classification of lung adenocarcinoma into molecular subtypes. EGFR, SOM, TP53
66  2019 Genome-Wide Analysis of Lung Adenocarcinoma Identifies Novel Prognostic Factors and a Prognostic Score. OS, PS, RFS, TNM
67  2019 Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma. ADH1C, OS, RFS, SPP1
68  2019 Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with Lung Adenocarcinoma. MCM
69  2019 Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma. DEGs, GSEA
70  2019 Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. AAH, AI, CPRIT
71  2019 Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation. CDK2, LUSC, PCNA
72  2019 HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis. EMT, HCP5, lncRNAs, miR-203, TGF-beta
73  2019 High Expression of FGF5 Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma. OS, RFS
74  2019 High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. KIF18A
75  2019 Histopathological Imaging⁻Environment Interactions in Cancer Modeling. ---
76  2019 HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma. DEGs, RFS
77  2019 Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma. CT
78  2019 Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma. ---
79  2019 Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma. lncRNA, PCG, timeROC
80  2019 Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma. ---
81  2019 Identification of a putative competitive endogenous RNA network for lung adenocarcinoma using TCGA datasets. ceRNA, FAM83A, miRs
82  2019 Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. OS
83  2019 Identification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinoma. Cav-1, DCN, DEGs
84  2019 Identification of Expression Signatures For Non-Small-Cell Lung Carcinoma Subtype Classification. lncRNA, LUSC, NSCLC, RFE
85  2019 Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases. ---
86  2019 Identification of lung-adenocarcinoma-related long non-coding RNAs by random walking on a competing endogenous RNA network. AUC, ceRNA, lncRNAs
87  2019 Identification of nine microRNAs as potential biomarkers for lung adenocarcinoma. DEmRNAs, qRT-PCR
88  2019 Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. miRNA-Seq, TCGA, TSmiR
89  2019 Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma. GNLY, Gzm M, GzmA, GzmB, PD-1, PD-L1, PRF1
90  2019 Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma. CX3CL1, CX3CR1, LUSC
91  2019 Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. Id1
92  2019 Integrated analysis reveals five potential ceRNA biomarkers in human lung adenocarcinoma. ceRNAs, DE, FENDRR, GEO, TF
93  2019 Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma. ---
94  2019 Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity. BrCa, ESCA, HR, OC, OS, PFS
95  2019 Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis. DUSP4, GGA2
96  2019 Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. ctDNA, ITH, ITHi, LUSC, NSCLC
97  2019 Involvement of Dual Strands of miR-143 (miR-143-5p and miR-143-3p) and Their Target Oncogenes in the Molecular Pathogenesis of Lung Adenocarcinoma. miRNAs
98  2019 Large-scale gene expression analysis reveals robust gene signatures for prognosis prediction in lung adenocarcinoma. GSEA
99  2019 LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma. EMT, LDHA
100  2019 LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response. lncRNA